Informações:
Falhas:
ID
19718
Descrição
Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT02307227
Link
https://clinicaltrials.gov/show/NCT02307227
Palavras-chave
Versões (1)
- 23/01/2017 23/01/2017 -
Transferido a
23 de janeiro de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Neoplasms NCT02307227
Eligibility Breast Neoplasms NCT02307227
- StudyEvent: Eligibility
Similar models
Eligibility Breast Neoplasms NCT02307227
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Breast Carcinoma | Evaluation HER2/Neu Status | immune status test
Item
histologically proven breast carcinoma evaluated for her 2 status and immune status
boolean
C0678222 (UMLS CUI [1])
C1261322 (UMLS CUI [2,1])
C1512413 (UMLS CUI [2,2])
C1657725 (UMLS CUI [3])
C1261322 (UMLS CUI [2,1])
C1512413 (UMLS CUI [2,2])
C1657725 (UMLS CUI [3])
Locally advanced breast cancer UICC (tumor staging)
Item
locally advanced carcinoma (uicc stage ii-iii)
boolean
C3495949 (UMLS CUI [1,1])
C0441914 (UMLS CUI [1,2])
C0441914 (UMLS CUI [1,2])
Age
Item
age < 70 years
boolean
C0001779 (UMLS CUI [1])
Measurable Disease
Item
measurable lesions
boolean
C1513041 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status 0-2
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy > 3 months
boolean
C0023671 (UMLS CUI [1])
Bone Marrow function | Liver function
Item
adequate bone marrow and hepatic functions
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
C0031843 (UMLS CUI [1,2])
C0232741 (UMLS CUI [2])
Creatinine clearance measurement
Item
creatinine clearance > 40 ml/min
boolean
C0373595 (UMLS CUI [1])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Patient Available Therapeutic procedure | Patient Available Follow-up
Item
patients must be accessible for treatment and follow up.
boolean
C0030705 (UMLS CUI [1,1])
C0470187 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0030705 (UMLS CUI [2,1])
C0470187 (UMLS CUI [2,2])
C3274571 (UMLS CUI [2,3])
C0470187 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0030705 (UMLS CUI [2,1])
C0470187 (UMLS CUI [2,2])
C3274571 (UMLS CUI [2,3])
Chemotherapy | Hormone Therapy
Item
prior chemotherapy or hormonal treatments
boolean
C0392920 (UMLS CUI [1])
C0279025 (UMLS CUI [2])
C0279025 (UMLS CUI [2])
Metastatic malignant neoplasm to brain
Item
brain metastases.
boolean
C0220650 (UMLS CUI [1])
curative treatment Neoplasm
Item
past or current history of neoplasm other than curatively treated.
boolean
C1273390 (UMLS CUI [1,1])
C0027651 (UMLS CUI [1,2])
C0027651 (UMLS CUI [1,2])
Investigational New Drugs
Item
concurrent treatment with other experimental drugs.
boolean
C0013230 (UMLS CUI [1])
Left ventricular ejection fraction
Item
left ventricular ejection fraction (lvef) <50 %
boolean
C0428772 (UMLS CUI [1])
nervous system disorder Significant | Mental disorders Significant
Item
history of significant neurological or psychiatric disorders.
boolean
C0027765 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0004936 (UMLS CUI [2,1])
C0750502 (UMLS CUI [2,2])
C0750502 (UMLS CUI [1,2])
C0004936 (UMLS CUI [2,1])
C0750502 (UMLS CUI [2,2])